載入中
NASDAQHealthcareBiotechnology
最新資料
US$90.78
+US$1.14 · +1.27%
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
前收盤價
US$90.78
+US$1.14 · +1.27%
盤中時間採用ET。市場資料可能有所延遲。
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
日內區間
目前US$90.78
52週區間
目前US$90.78
盤中時間採用ET。市場資料可能有所延遲。
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
日內區間
目前US$90.78
52週區間
目前US$90.78
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.9億 USD | 1.3億 USD | 7742.8萬 USD | 2363.8萬 USD | 315.4萬 USD |
| 銷貨成本 | 1949.2萬 USD | 1336.8萬 USD | 930.2萬 USD | 213.3萬 USD | 59.9萬 USD |
| 毛利 | 1.7億 USD | 1.17億 USD | 6812.6萬 USD | 2150.5萬 USD | 255.5萬 USD |
| 研究與開發 | 1.67億 USD | 2.38億 USD | 1.35億 USD | 1.09億 USD | 1.04億 USD |
| 銷售、一般及管理費用 | 1.95億 USD | 1.44億 USD | 1.18億 USD | 9203.2萬 USD | 6848.6萬 USD |
| 營業費用 | 3.62億 USD | 3.82億 USD | 2.52億 USD | 2.01億 USD | 1.73億 USD |
| 利息收入 | 1529.3萬 USD | 1471.1萬 USD | 1394.5萬 USD | 402.9萬 USD | 44.7萬 USD |
| 利息支出 | 2058.3萬 USD | 2060.3萬 USD | 1389.2萬 USD | 520.1萬 USD | — |
| 折舊和攤銷 | 133.8萬 USD | 156.3萬 USD | 175.8萬 USD | 167.2萬 USD | 115.8萬 USD |
| 營業利益 | −1.92億 USD | −2.66億 USD | −1.84億 USD | −1.79億 USD | −1.7億 USD |
| 淨利 | −1.97億 USD | −2.61億 USD | −1.85億 USD | −1.81億 USD | −6961.2萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$146.83
上漲空間 61.74%AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
